Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016

09 Mar 2010 • by Natalie Aster
GlobalData, the industry analysis specialist, has released its latest research “Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016”. The report provides key data, information and analysis on the global acute coronary syndrome disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need or commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for the future market competition is also outlined.

The Acute Coronary Syndrome Market is Estimated to Shrink at a Compound Annual Growth Rate (CAGR) of 1% from 2009 to 2016

The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in 2009 and is forecast to decline by 1% annually for the next seven years to reach $949m in 2016. This decline in market size is primarily due to the patent expirations of six branded drugs which will subsequently allow the entry of generics.

Current Treatment Options Cater to Most of the Market Needs

At present the ACS market is competitive with six approved drugs. The dominant class of drug is glycoprotein (GP) IIb/IIIa receptor antagonist. Plavix is an ADP mediated GP IIb/IIIa receptor antagonist in combination with aspirin and dominates the market. Lovenox which was approved in 2007 dominates the Percutaneous Coronary Intervention (PCI) treatment segment of the ACS market. The heavy intracranial bleeding and abdominal bleeding associated with high doses of these anti coagulants leaves a significant area of unmet need for a new entrant.

Competitive Acute Coronary Syndrome Market Consists of Six Approved Drugs and Off Label Usages

Sanofi-Aventis, GlaxoSmithKline (GSK), and Bristol-Myers Squibb, are the leading competitors in the global ACS market. The competitive landscape is moderately populated with six products, three of which can be described as strong. This market is characterized by moderate levels of off label usage.

Strong Pipeline Consists of Many First-in-Class Drugs in Phase III

Approximately 42 clinical studies were in different developmental stages in 2009. Brilinta, Arixtra, and Apixaban, are the key products currently in the pipeline. Brilinta is a me-too drug that is expected to be more efficacious than Plavix. Factor Xa inhibitors are the dominate class of anti coagulants found in the later stages of the pipeline. The early stages of the pipeline consist of novel molecules that potentially can induce disease modification.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.